Circular Genomics Unveils Its CircPATH™ Platform Following Landmark Nature Medicine Study Demonstrating Breakthrough Performance in Early Detection of Alzheimer's Disease

Blood-Based Circular RNA Biomarkers Outperform Gold-Standard Tests, Enable Preclinical Risk Stratification Years Before Symptom Onset, and Open New Era in Precision Neurology Highlights of Circular Genomics' Alzheimer's assays: validated across nearly 2,400 individuals in three...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.